Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025
November 28, 2025 | obesity
As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected on the latest research, the shifting clinical landscape, and how collaboration across disciplines can improve care for people living with obesity.
In this post-event roundtable, Matt Wadyka (Inizio Medical), Alexis Cogswell (Real-World iNSIGHTS, Inizio Medical), Varun Renjen MD (Putnam, part of Inizio Advisory), and Elaine Ferguson (Inizio Medical) share their perspectives on what’s shaping the next phase of obesity care.
Putting patients at the center of decision-making
Matt Wadyka, Senior Vice President at Inizio Medical, reflected on how the voice of the person living with obesity is becoming central to clinical progress.
“What I’m most excited about is the evolving role of the patient in their own decision-making when it comes to healthcare with obesity,” said Matt. “With multidisciplinary teams in attendance, it’s clear that keeping the patient at the center is foundational to making the right decisions for the right person at the right time.”
He also noted that the pace of innovation is accelerating rapidly, with new entrants transforming the scientific dialogue.
“For a long time, there were only a couple of major players in the space,” he explained. “Now, with so many new companies and modalities, we’re seeing an explosion of new science that’s changing how we think about treatment, and even how we define the disease itself.”
Redefining obesity through data and real-world insight
Alexis Cogswell, Vice President, Real-World iNSIGHTS, Inizio Medical, emphasized that the shift toward recognizing obesity as a chronic, multifactorial condition is reshaping how data is applied in practice.
“At Real-World iNSIGHTS, we’re really interested in understanding how new data are being taken into clinical practice by providers globally,” said Alexis. “The reframing of obesity as a chronic condition makes perfect sense given the breadth of GLP-1 approvals in recent years.”
She also previewed the upcoming Clinical Excellence Summit in Obesity, taking place next April, which will explore how groundbreaking research presented at ObesityWeek® is influencing clinical decisions.
“We’ll be looking at how these treatments are being used for the people who need them most, with conversations that include patients, providers and payers.”
Redefining the science of obesity
For Varun Renjen MD, Partner at Putnam (part of Inizio Advisory), one of the biggest scientific shifts is the very definition of obesity itself.
“It’s not just about reducing weight from a BMI perspective,” said Varun. “Obesity is a complex heterogenous physiological process that affects multiple organs – the heart, kidney, lungs, liver, and even the brain across the same pathway. There is a clear pathological process in obesity that affects the whole body”
He described the meeting as a sign that the field is entering a new era of treating obesity including precision and personalization.
“We’re at the beginning of a true scientific revolution, redefining what obesity is as potentially cardiometabolic dysfunction, how it’s treated, and how care is customized across the patient journey. Whether it’s moving between therapies, mechanisms, modalities or quality of weight loss, we’re learning how to adapt treatments as people progress with GLP-1s and beyond. If in the past cancer was treated with chemotherapy and has rapidly progressed to different modalities and segments; that is where we are going with obesity.”
From weight loss to whole-body health
Elaine Ferguson, Global President, Inizio Medical, highlighted the remarkable diversity of science showcased this year.
“There’s been a real breadth of science this week, and the biggest impact for me is seeing all the different pathways and mechanisms under investigation,” said Elaine. “We’re seeing ambitious trial designs and outcomes that go far beyond weight loss, looking at organ protection and whole-body health.”
She also underscored the importance of hearing directly from people living with obesity at the congress.
“It’s been inspiring to hear their experiences – not just in terms of physical changes, but the overall improvements in health, energy, and quality of life.”
Looking ahead
Reflecting on the week, Matt summed up the opportunity ahead:
“Right now, there’s a big emphasis on insights. Next, it’ll be about data, and then the focus will turn to access and affordability. This is a pivotal moment to be part of the obesity field.”
From redefining the science to centering lived experience, the energy and collaboration seen at ObesityWeek® 2025 reaffirm that the field is moving fast, and Inizio is proud to be part of shaping its future.
Discover more about how Inizio is driving innovation across the obesity landscape
This content was provided by Inizio
Company Details
Latest Content from Inizio
Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development
Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and...
Infographic: Therapy Watch Acute Myeloid Leukemia market snapshot
This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across...
Navigating the future of AI: Insights from EphMRA’s one day meeting in London
Authored by: Ellie Forde and Mark Braund, Directors
Research conducted for Johnson and Johnson published in scientific journal
Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.
Connecting our Inizio Advisory capabilities to help a client address a threat to the brand, guide strategy and improve brand performance
The challenge Our client knew that prescribing of a key brand in a major market had slowed and needed to understand which patient segments were impacted so they could address...
Autoimmune conditions: Living With syndicated patient reports
The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care. In our...
How we elevated HCP market research engagement and insights using AI avatars for an immersive experience
Our client required an effective strategy for promoting discussions about self-paid vaccines with healthcare professionals (HCPs) during patient consultations. The conventional method of conducting market research would typically only deliver...
How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution
PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...
The risk of replicating social bias in synthetic patient data – The need for human intelligence partnered with AI
Authored by Paul Reed and Anabelle Gall
Latest European developments and new talent at Research Partnership
Angela Duffy has been appointed as Managing Director for our European based ad hoc research teams. Angela has been an integral part of Research Partnership for 19 years, witnessing its...